Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | JNJ-95566692 |
| Synonyms | |
| Therapy Description |
Limited information is currently available on JNJ-95566692, a putative trispecific antibody targeting CD79b, MS4A1 (CD20), and CD3 (Feb 2026). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| JNJ-95566692 | JNJ95566692|JNJ 95566692 | CD20 Antibody 28 CD3 Antibody 123 | Limited information is currently available on JNJ-95566692, a putative trispecific antibody targeting CD79b, MS4A1 (CD20), and CD3 (Feb 2026). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|